Show simple item record

dc.contributor.advisorZuluaga Cristancho, Eduardo Alirio 
dc.contributor.advisorBuitrago-Medina, Daniel-Alejandro 
dc.creatorZuluaga Liberato, Andrea Marcela 
dc.creatorGuavita Navarro, Diana Katherine 
dc.date.accessioned2019-02-18T22:42:09Z
dc.date.available2019-02-18T22:42:09Z
dc.date.created2019-02-06
dc.date.issued2019
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/19102
dc.descriptionIntroducción: El cáncer gástrico es la quinta malignidad más común en el mundo, y la tercera causa de muerte por cáncer en el mundo. Es importante conocer en Colombia la supervivencia global y libre de enfermedad a 5 años, así como factores pronósticos. Métodos: Se revisaron 106 historias clínicas de un centro oncológico de Bogotá, Colombia de Enero de 2005 a Junio de 2018, se realizó un análisis de supervivencia con método de Kaplan Meier, prueba Log-rank y Regresión de COX. Resultados: La mediana de seguimiento fue 21 meses, la mayoría de pacientes fueron hombres (53.7%), con diagnóstico temprano en 63.2% (estadios 0, I y II), mediana de edad al diagnóstico de 57.8 años, cero ganglios comprometidos (44.3%), tipo histológico intestinal (45.3%) y pobre grado de diferenciación tumoral (57.5%). La supervivencia libre de enfermedad a 1, 3 y 5 años fue de 84%, 53% y 46.3%; y la supervivencia global de 94.1%, 82% y 69.4%. Como factor pronóstico, se encontró que el mayor número de ganglios comprometidos al diagnóstico disminuye la supervivencia libre de enfermedad, (1-2 ganglios: HR 6.46 IC95%1.16-35.92; 3-6 ganglios: HR 4.44 IC95% 1.25-15.77; y ≥7 ganglios: HR 10.84 IC95% 3.57-32.9) y disminuye la supervivencia global (≥7 ganglios: HR 6.56 IC95% 1.69-25.37). Conclusión: La supervivencia global y libre de enfermedad fue mayor que la descrita en la literatura; se encontró el número de ganglios comprometidos al diagnóstico como factor de riesgo para mortalidad y recaídas más tempranas.
dc.description.abstractIntroduction: Gastric cancer is the fifth most common malignancy in the world, and the third cause of cancer death in the world. It is important to know in Colombia the global survival and the disease-free survival at 5 years, as well as prognostic factors. Methods: We reviewed 106 medical records of a cancer center in Bogotá, Colombia from January 2005 to June 2018. We performed a survival analysis using the Kaplan Meier method, Log-rank test and COX regression. Results: The median follow-up was 21 months, the majority of patients were males (53.7%), have early diagnosis in 63.2% (stages 0, I and II), median age of diagnosis of 57.8 years, have none lymph node involved (44.3%), intestinal histological type (45.3%) and poorly differentiated (57.5%). Disease-free survival at 1, 3 and 5 years was 84%, 53% and 46.3%; and overall survival was 94.1%, 82% and 69.4%. The number of lymph nodes involved in the diagnosis of disease-free survival was found as a prognostic factor (1-2 lymph nodes: HR 6.46 IC95% 1.16-35.92, 3-6 nodes: HR 4.44 IC95% 1.25-15.77, and ≥7 nodes: HR 10.84 IC95% 3.57-32.9) and for overall survival (≥7 nodes: HR 6.56 IC95% 1.69-25.37). Conclusion: The overall survival and disease free survival was greater than the described in the literature, finding as a risk factor for disease-free survival and overall survival, the number of lymph nodes involved at diagnosis.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectCáncer gástrico
dc.subjectAnálisis de supervivencia
dc.subjectRecaída
dc.subjectMortalidad
dc.subject.ddcEnfermedades 
dc.subject.lembEnfermedades del estómago
dc.subject.lembNeoplasias gástricas
dc.titleSupervivencia en una cohorte de pacientes con adenocarcinoma gástrico resecable, Bogotá, 2005-2018
dc.typemasterThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Medicina Interna
dc.publisher.programEspecialización en Medicina Interna
dc.publisher.departmentFacultad de Medicina
dc.subject.keywordGastric cancer
dc.subject.keywordsurvival analysis
dc.subject.keywordrelapse
dc.subject.keywordmortality
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto Completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationLee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. 2016. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 150:1113-1124.e5.
dc.source.bibliographicCitationHa TH, Kim BG, Jeong D, Oh S, Kim W, Jung YJ, Ahn DW, Jeong JB, Kim JW, Lee KL, Koh SJ. 2017. Alcoholic Liver Disease Is Associated with an Increased Risk of Gastric Cancer. Dig Dis Sci 62:273-279.
dc.source.bibliographicCitationNelen SD, Verhoeven RH, Lemmens VE, de Wilt JH, Bosscha K. 2017. Incremento de la brecha de supervivencia entre pacietne jovenes y ancianos con cancer gastrico. Gastric Cancer.
dc.source.bibliographicCitationvan Gestel YR, Lemmens VE, de Hingh IH, Steevens J, Rutten HJ, Nieuwenhuijzen GA, van Dam RM, Siersema PD. 2013. Influencia de las comorbilidades y la edad en las tasas de mortalidad postoperatoria, a 1,2 y 3 meses en pacientes con cancer gastrointestinal. Ann Surg Oncol 20:371-80.
dc.source.bibliographicCitationMinisterio de Salud y Protección Social. (2017). Boletín del aseguramiento en Salud. Recuperado de: https://www.minsalud.gov.co
dc.source.bibliographicCitationMarqués-Lespier JM, González-Pons M, Cruz-Correa M. 2016. Perspectivas actuales sobre el cancer gastrico. Gastroenterol Clin North Am 45:413-28.
dc.source.bibliographicCitationMontoya M. 2016. Caracterización de 130 pacientes sometidos a gastrectomía por cáncer gástrico en el Instituto de Cancerología---Clínica Las Américas de Medellín. revista colombiana de cancerologia 20:73-78.
dc.source.bibliographicCitationCancerología. INd. 2001. Guías de Práctica Clínica en Enfermedades Neoplásicas. DC B, ministerio de salud.
dc.source.bibliographicCitationCorrea P, Piazuelo MB. 2012. The gastric precancerous cascade. J Dig Dis 13:2-9.
dc.source.bibliographicCitationPiazuelo MB, Correa P. 2013. Gastric cáncer: Overview. Colomb Med (Cali) 44:192-201.
dc.source.bibliographicCitationFigueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-Simões M. 2002. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94:1680-7.
dc.source.bibliographicCitationCamargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, Lissowska J, Kim S, Hu N, Gonzalez CA, Yatabe Y, Koriyama C, Hewitt SM, Akiba S, Gulley ML, Taylor PR, Rabkin CS. 2014. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 63:236-43.
dc.source.bibliographicCitationWYNDER EL, KMET J, DUNGAL N, SEGI M. 1963. AN EPIDEMIOLOGICAL INVESTIGATION OF GASTRIC CANCER. Cancer 16:1461-96.
dc.source.bibliographicCitationBarstad B, Sørensen TI, Tjønneland A, Johansen D, Becker U, Andersen IB, Grønbaek M. 2005. Intake of wine, beer and spirits and risk of gastric cancer. Eur J Cancer Prev 14:239-43.
dc.source.bibliographicCitationZhu H, Yang X, Zhang C, Zhu C, Tao G, Zhao L, Tang S, Shu Z, Cai J, Dai S, Qin Q, Xu L, Cheng H, Sun X. 2013. Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. PLoS One 8:e70955.
dc.source.bibliographicCitationMachida-Montani A, Sasazuki S, Inoue M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Hanaoka T, Tsugane S. 2004. Association of Helicobacter pylori infection and environmental factors in non-cardia gastric cancer in Japan. Gastric Cancer 7:46-53.
dc.source.bibliographicCitationAssociation JGC. 2011. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101-12.
dc.source.bibliographicCitationLAUREN P. 1965. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand 64:31-49.
dc.source.bibliographicCitationAnonymous. 2003. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 58:S3-43.
dc.source.bibliographicCitationLambert R. 2012. Endoscopy in screening for digestive cancer. World J Gastrointest Endosc 4:518-25.
dc.source.bibliographicCitationWaddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, (ESMO) ESfMO, (ESSO) ESoSO, (ESTRO) ESoRaO. 2014. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 40:584-91.
dc.source.bibliographicCitationKobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S, Group JS. 2002. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. Int J Cancer 102:39-44.
dc.source.bibliographicCitationCao Y, Zhang G, Wang P, Zhou J, Gan W, Song Y, Huang L, Zhang Y, Luo G, Gong J, Zhang L. 2017. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol 17:2.
dc.source.bibliographicCitationMartín Alonso Gómez Zuleta M, Javier Humberto Riveros Vega, MD, Oscar Ruiz, MD, Alejandro Concha, MD. 2015. Guía de práctica clínica para la prevención, diagnóstico y tratamiento del cáncer gástrico revista colombiana de gastroenterologia 30:34-42.
dc.source.bibliographicCitationBlakely AM, Miner TJ. 2013. Surgical considerations in the treatment of gastric cancer. Gastroenterol Clin North Am 42:337-57.
dc.source.bibliographicCitationBurke EC, Karpeh MS, Conlon KC, Brennan MF. 1997. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 225:262-7.
dc.source.bibliographicCitationPower DG, Schattner MA, Gerdes H, Brenner B, Markowitz AJ, Capanu M, Coit DG, Brennan M, Kelsen DP, Shah MA. 2009. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 208:173-8.
dc.source.bibliographicCitationSmyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, Committee EG. 2016. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v38-v49.
dc.source.bibliographicCitationSongun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. 2010. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439-49.
dc.source.bibliographicCitationYu W, Choi GS, Chung HY. 2006. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 93:559-63.
dc.source.bibliographicCitationNicolás Isa O. MRN, Hernán López V. 2014. Radioquimioterapia adyuvante en cáncer gástrico completamente resecado: experiencia del Instituto Nacional del Cáncer de Chile. revista medica de chile 142:199- 203.
dc.source.bibliographicCitationCunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. 2006. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20.
dc.source.bibliographicCitationBang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Ji J, Yeh TS, Button P, Sirzén F, Noh SH, investigators Ct. 2012. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315-21.
dc.source.bibliographicCitationMacdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. 2001. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-30.
dc.source.bibliographicCitationMiner TJ, Brennan MF, Jaques DP. 2004. A prospective, symptom related, outcomes analysis of 1022 palliative procedures for advanced cancer. Ann Surg 240:719-26; discussion 726-7.
dc.source.bibliographicCitationNagaraja V, Eslick GD, Cox MR. 2014. Endoscopic stenting versus operative gastrojejunostomy for malignant gastric outlet obstruction-a systematic review and meta-analysis of randomized and non-randomized trials. J Gastrointest Oncol 5:92-8.
dc.source.bibliographicCitationHsu JT, Liao JA, Chuang HC, Chen TD, Chen TH, Kuo CJ, Lin CJ, Chou WC, Yeh TS, Jan YY. 2017. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care 16:19.
dc.source.bibliographicCitationJucá PC, Lourenço L, Kesley R, Mello EL, Oliveira IM, Correa JH. 2012. Comparison of survival and prognostic factors in patients with gastric adenocarcinoma in T2 and T3. Rev Col Bras Cir 39:377-84.
dc.source.bibliographicCitationAdham D, Abbasgholizadeh N, Abazari M. 2017. Prognostic Factors for Survival in Patients with Gastric Cancer using a Random Survival Forest. Asian Pac J Cancer Prev 18:129-134.
dc.source.bibliographicCitationFabio Grosso RByLV. 2013. Supervivencia en adenocarcinoma gástrico posterior a tratamiento adyuvante tratados en el Instituto Nacional de Cancerología de Colombia durante el 2009 . revista colombiana de cancerologia 17:55-61.
dc.source.bibliographicCitationSuzuki T, Shimada H, Nanami T, Oshima Y, Yajima S, Ito M, Washizawa N, Kaneko H. 2016. Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patients with gastric cancer. Surg Today 46:1394-1401.
dc.source.bibliographicCitationLiu S, Feng F, Xu G, Liu Z, Tian Y, Guo M, Lian X, Cai L, Fan D, Zhang H. 2016. Clinicopathological features and prognosis of gastric cancer in young patients. BMC Cancer 16:478.
dc.source.bibliographicCitationChen J, Xu Y, Long Z, Zhou Y, Zhu H, Wang Y, Shi Y. 2016. Impact of Age on the Prognosis of Operable Gastric Cancer Patients: An Analysis Based on SEER Database. Medicine (Baltimore) 95:e3944.
dc.source.bibliographicCitationGao H, Lan X, Li S, Xue Y. 2016. [Clinicopathologic characteristics and prognostic factors of gastric cancer in the elderly patients over 75 years]. Zhonghua Wei Chang Wai Ke Za Zhi 19:522-5.
dc.source.bibliographicCitationLuo T, Chen W, Wang L, Zhao H. 2016. CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study. Medicine (Baltimore) 95:e5297.
dc.source.bibliographicCitationChang JM, Lara KA, Gray RJ, Pockaj BA, Wasif N. 2017. Clinical Outcomes after Surgery for Linitis Plastica of the Stomach: Analysis of a Population Cancer Registry. Am Surg 83:23-29.
dc.source.bibliographicCitationThompson RJ, Ranaghan L, Kennedy R, Clements W, Carey PD, Kennedy JA. 2017. Survival following operative management of gastric linitis plastica compared with non-operative management. Ann R Coll Surg Engl 99:228-232.
dc.source.bibliographicCitationZhang L, Huang Z, Zhang H, Zhu M, Zhu W, Zhou X, Liu P. 2017. Prognostic value of candidate microRNAs in gastric cancer: A validation study. Cancer Biomark 18:221-230.
dc.source.bibliographicCitationJunior PN, Neto RA, Forones NM. 2016. HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER. Arq Gastroenterol 53:62-7.
dc.source.bibliographicCitationTakaya K, Takahashi R, Honma S, Horii S, Takahashi H, Hagiwara M, Chin M, Hashizume E. 2016. [A Case of HER2-Positive Stage IV Advanced Gastric Cancer Treated with Chemotherapy Combined with Trastuzumab]. Gan To Kagaku Ryoho 43:1113-6.
dc.source.bibliographicCitationRen C, Chen H, Han C, Fu D, Wang D, Shen M. 2016. High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer. J Cancer Res Clin Oncol 142:2489-2496.
dc.source.bibliographicCitationZhou X, Xu L, Huang Z, Zhang L, Zhang H, Zhu W, Liu P. 2016. The hematologic markers as prognostic factors in patients with resectable gastric cancer. Cancer Biomark 17:359-367.
dc.source.bibliographicCitationMusri FY, Mutlu H, Eryilmaz MK, Salim DK, Gunduz S, Coskun HS. 2016. The Neutrophil to Lymphocyte Ratio is an Independent Prognostic Factor in Patients with Metastatic Gastric Cancer. Asian Pac J Cancer Prev 17:1309-12.
dc.source.bibliographicCitationChen SL, Li JP, Li LF, Zeng T, He X. 2016. Elevated Preoperative Serum Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) Ratio Is Associated with Better Prognosis in Patients Undergoing Curative Treatment for Gastric Adenocarcinoma. Int J Mol Sci 17.
dc.source.bibliographicCitationHu D, Peng F, Lin X, Chen G, Zhang H, Liang B, Ji K, Lin J, Chen LF, Zheng X, Niu W. 2017. Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study. EBioMedicine 15:73-80.
dc.source.bibliographicCitationZhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, Ma LL, Yu Z, Shen X. 2016. Sarcopenia is an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer
dc.source.bibliographicCitationKim DJ, Seo SH, Kim KH, Park YH, An MS, Bae KB, Choi CS, Oh SH. 2016. Comparisons of clinicopathologic factors and survival rates between laparoscopic and open gastrectomy in gastric cancer. Int J Surg 34:161-168.
dc.source.bibliographicCitationIshigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. 2017. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 20:128-134.
dc.source.bibliographicCitationZhao J, Du F, Zhang Y, Kan J, Dong L, Shen G, Zheng F, Chen H, Ji F, Luo Y, Ma F, Wang Z, Xu B. 2016. Impact on long-term survival of the number of lymph nodes resected in patients with pT1N0 gastric cancer after R0 resection: A multicenter study in China. Medicine (Baltimore) 95:e4420.
dc.source.bibliographicCitationOh SE, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S. 2017. Prognostic implication of hepatoduodenal ligament lymph nodes in gastric cancer. Medicine (Baltimore) 96:e6464.
dc.source.bibliographicCitationLu M, Yang Z, Feng Q, Yu M, Zhang Y, Mao C, Shen L, Tang J. 2016. The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients. Medicine (Baltimore) 95:e4052.
dc.source.bibliographicCitationFeng F, Tian Y, Guo M, Liu S, Xu G, Liu Z, Zheng G, Lian X, Fan D, Zhang H. 2017. Comparison of clinicopathological features and prognosis of gastric cancer located in the lesser and greater curve. Clin Transl Oncol 19:457-463.
dc.source.bibliographicCitationLiu Z, Liu S, Zheng G, Yang J, Hong L, Sun L, Fan D, Zhang H, Feng F. 2016. Clinicopathological features and prognosis of coexistence of gastric gastrointestinal stromal tumor and gastric cancer. Medicine (Baltimore) 95:e5373.
dc.source.bibliographicCitationKim Y, Ejaz A, Spolverato G, Squires MH, Poultsides G, Fields RC, et al. Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the us gastric cancer collaborative. Ann Surg Oncol. 2015;22(2):557-64.
dc.source.bibliographicCitationCarvajal A, Oliveros M, Zapata S. desenlaces quirúrgicos en pacientes con cáncer gástrico sometidos a gastrectomía abierta vs gastrectomía laparoscopica en el hospital Erasmo Meoz en la ciudad de cúcuta, Colombia, entre el año 2012 y 2014. 2017.
dc.source.bibliographicCitationLee JW, Ali B, Yoo HM, Park CH, Song KY. Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy. BMC Cancer. 2015;15:1005.
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.type.documentTrabajo de grado
dc.creator.degreetypeFull time


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 2.5 Colombia